Palo Alto, United States
23andMe is a nonprofit organization at the forefront of genetic research, founded in 2006 in the United States. This entity operates within the Biotechnology and Life Sciences industries, with a mission encapsulated by its slogan: "A nonprofit advancing health through the power of genetics and crowdsourced research."
The organization's 23andMe Research Institute empowers individuals with access to personal genetic information, while fostering participation in one of the world's largest crowdsourced research initiatives. Their ultimate aim is to significantly propel scientific knowledge and improve human health through a deepened understanding of DNA.
Though nonprofit, the institute recently caught the attention of investors. In a substantial financial event, they secured a $256.00M bankruptcy investment on 01 May 2025, led by Regeneron Pharmaceuticals. This notable backing highlights wide recognition of their potential to influence genetic research and healthcare advancements.
